CV can be used as a therapeutic agent in acute respiratory distress syndrome (ARDS) due to its inhibition of the activation of nuclear factor kinase (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways [58]. The gene discussed is NFKB1; the disease is acute respiratory distress syndrome.